Welcome to the Stock of the Day!
Hot Casino Companies To Watch In Right Now: Energy and Minerals Australia Ltd (EMA)
Energy & Minerals Australia Limited is an Australia-based uranium exploration and development company. During the fiscal year ended June 30, 2012 (fiscal 2012), the Company continued with exploration and development of its tenement package and progression of development studies on the Mulga Rock project. The Company operates one business segment: exploration. The activities undertaken by the exploration segment includes the exploration on tenements in Western Australia and scoping study activities on the Mulga Rock project. The Mulga Rock project is located about 250 Kilometer northeast of Kalgoorlie. The Mulga Rock Deposits (MRD) comprises four separate deposits being: Ambassador, Emperor ,Shogun and the Princess Deposit, The Company holds over 900 square kilometers of land surrounding the MRD. Narnoo Mining Pty Ltd, a wholly owned subsidiary of the Company , is the registered holder of exploration licenses numbered E39/876 and E39/877. Advisors' Opinion:- [By Tom Aspray, Senior Editor, MoneyShow.com]
To calculate the Mass Index:
Calculate a nine-day exponential moving average (EMA) of the difference between the high and low prices. Calculate a nine-day exponential moving average of the moving average calculated in Step 1. Divide the moving average calculated in Step 1 by the moving average calculated in Step 2. Total the values in Step 3 for the number of periods in the Mass Index (e.g., 25 days).
10 Best Oil Service Stocks To Invest In Right Now: Hannover House Inc (HHSE)
Hannover House, Inc., formerly Target Development Group, Inc., is the parent company of Hannover House. Hannover House is a full service media company, specializing in the production and distribution of feature films onto the digital versatile disc (DVD) format for the North American retail marketplace. As of December 31, 2010, the Company had over 70 DVD titles in active distribution. In June 2012, the Company acquired nine feature films for video release in North America.
Retailers carrying Hannover House products include independently owned and operated retail video stores and book stores, including Barnes & Noble, Best Buy, Blockbuster Video, Borders Group, Fred Meyer Group, Hastings, SAM�� Club, Transworld Group and Wal-Mart. It also includes Internet retailers.
Advisors' Opinion:- [By Peter Graham]
Small cap tech or media stocks Thinspace Technology Inc (OTCMKTS: THNS), Beamz Interactive Inc (OTCBB: BZIC) and Hannover House Inc (OTCMKTS: HHSE) have been getting some extra attention lately, but it appears that only one of these stocks has been the subject of a paid promotion. Nevertheless, all three stocks have been busy with press releases trying to get the attention of investors or traders. So are these three small cap tech or media stocks worth your attention? Here is a closer look along with a reality check:
10 Best Oil Service Stocks To Invest In Right Now: Watsco Inc.(WSO)
Watsco, Inc., together with its subsidiaries, engages in the distribution of air conditioning, heating, and refrigeration equipment in the United States. It distributes residential central air conditioners; gas, electric, and oil furnaces; commercial air conditioning and heating equipment and systems; and other specialized equipments. The company also distributes various parts, including replacement compressors, evaporator coils, motors, and other component parts; and supplies comprising thermostats, insulation material, refrigerants, ductwork, grills, registers, sheet metal, tools, copper tubing, concrete pads, tape, adhesives, and other ancillary supplies. It serves approximately 50,000 contractors and dealers that service the replacement and new construction markets. The company also exports its products to Latin America and the Caribbean. Watsco, Inc. was founded in 1945 and is headquartered in Miami, Florida.
Advisors' Opinion:- [By Michael Flannelly]
Watsco Inc (WSO), a distributor of air conditioning, heating, and refrigeration equipment, announced early on Wednesday that it is raising its quarterly dividend payout by 60%.
The company will now pay a quarterly dividend of 40 cents per share, up from the previous payout of 25 cents per share. This dividend will be paid on October 31 to shareholders of record on October 15, with an ex-dividend date of October 10.
Albert H. Nahmad, Watsco’s Chairman & Chief Executive Officer stated, “Our philosophy of sharing cash flow through dividends continues. As we have stated many times in the past, our goal over the long-term is to pay increasing dividends while maintaining a conservative balance sheet with capacity to make investments in our business and build our network. We will consider future increases in light of such investment opportunities, cash flow, general economic conditions and our overall financial condition.��/p>
Watsco shares were inactive during pre-market trading on Wednesday. The stock is up 25.49% year-to-date.
- [By Greg Williamson]
A successful HVAC distribution company with great growth potential
An excellent way to profit from these tailwinds is by investing in Watsco (NYSE: WSO ) (NYSE: WSO ) (NYSE: WSO ) . Watsco is a leading distributor of HVAC equipment, with more than 570 locations in the U.S., Canada, Mexico, and Puerto Rico. Watsco also exports products to Latin America and the Caribbean. - [By Marc Bastow]
HVAC parts and components distributor Watsco (WSO) announced a 60% dividend increase to 40 cents per share, payable Oct. 31 to shareholders of record as of Oct. 10.
WSO Dividend Yield: 1.7%
10 Best Oil Service Stocks To Invest In Right Now: Wyndham Worldwide Corp(WYN)
Wyndham Worldwide Corporation, together with its subsidiaries, provides various hospitality products and services to individual consumers and business customers in the United States and internationally. It offers its products and services under the Wyndham Hotels and Resorts, Ramada, Days Inn, Super 8, Howard Johnson, Wyndham Rewards, Wingate by Wyndham, Microtel, RCI, The Registry Collection, ResortQuest, Landal GreenParks, Novasol, Hoseasons, cottages4you, James Villa Holidays, Wyndham Vacation Resorts, and WorldMark by Wyndham brand names. The company?s Lodging segment franchises hotels in the upscale, midscale, economy, and extended stay markets of the lodging industry, as well as provides hotel management services for full-service hotels. Its Vacation Exchange and Rentals segment provides vacation exchange products and services, as well as access to distribution systems and networks to resort developers and owners of intervals of vacation ownership interests (VOIs); a nd markets vacation rental properties primarily on behalf of independent owners, vacation ownership developers, and other hospitality providers. Wyndham Worldwide Corporation?s Vacation Ownership segment develops and markets VOIs to individual consumers; and provides consumer financing in connection with the sale of VOIs, as well as offers property management services at resorts. The company is headquartered in Parsippany, New Jersey.
Advisors' Opinion:- [By Ben Levisohn]
Companies that have had earnings revisions rise during the second quarter and are likely to beat earnings include Wyndham Worldwide (WYN),�CBRE Group (CBG), Consol Energy (CNX), McKesson (MCK) and Boston Properties (BXP), Sneider says.
10 Best Oil Service Stocks To Invest In Right Now: Tile Shop Holdings Inc (TTS)
Tile Shop Holdings, Inc., incorporated on June 21, 2012, is a specialty retailer of manufactured and natural stone tiles, setting and maintenance materials, and related accessories in the United States. The Company sells over 4,500 products from around the world, including ceramic, porcelain, glass, and stainless steel manufactured tiles and, marble, granite, quartz, sandstone, travertine, slate, and onyx natural tiles. It purchases its tile products and accessories directly from producers. The Company manufactures its own setting and maintenance materials, such as thinset, grout, and sealers under its brand name. The Company operates 70 stores in 22 states, with an average size of 23,000 square feet. It also sells its products on its Website. In January 2014 Tile Shop Holdings Inc launched its first retail store in Oklahoma City.
The Company offers a complete assortment of tile products, generally sourced directly from producers, including ceramic, porcelain, glass, and stainless steel manufactured tiles, and marble, granite, quartz, sandstone, travertine, slate, and onyx natural tiles. The Company also offers a range of setting and maintenance materials, such as thinset, grout and sealers, and accessories, including installation tools, shower and bath caddies, drains, and similar products.
The Company competes with Home Depot, Tile America, World of Tile, Century Tile, and Floor and Decor, Dal-Tile and Florida Tile.
Advisors' Opinion:- [By Tim Melvin]
Tile Shops Holdings (TTS) came public back in 2012 and was initially a hot deal, doubling in the months after the deal was priced. It has been pretty much downhill from there, and the shares have lost half their peak value and are back near the offering price.
- [By Demitrios Kalogeropoulos]
The Tile Shop's (NASDAQ: TTS ) shares fell 11% yesterday despite no news coming from the company. Instead, investors were spooked by a big profit warning from a seemingly unrelated retailer: Lumber Liquidators (NYSE: LL ) .�
10 Best Oil Service Stocks To Invest In Right Now: iShares 1-3 Year Credit Bond ETF (CSJ)
iShares Lehman 1-3 Year Credit Bond Fund (the Fund) seeks investment results that correspond to the price and yield performance of the investment-grade credit sector of the United States bond market as defined by the Lehman Brothers 1-3 Year U.S. Credit Index (the Index). The Index measures the performance of investment-grade United States credit securities, corporate debt and sovereign, local authority and non-United States agency bonds that are United States dollar denominated.
The Fund invests in a representative sample of the securities in the Index, which has a similar investment profile as the Index. The Index includes investment grade United States credit securities that have a remaining maturity of greater than or equal to one year and less than three years, and have more than $250 million or more of outstanding face value. Barclays Global Fund Advisors serves as an advisor to the Fund.
Advisors' Opinion:- [By GURUFOCUS]
In addition to individual stocks several funds pay a monthly dividend. Below is a sampling of these:
Monthly Bond Funds- iShares Barclays 1-3 Year Credit Bond (CSJ) | Yield: 1.29%
- Vanguard Short-Term Bond ETF (BSV) | Yield: 1.25%
- Vanguard Intermediate-Term Bond ETF (BIV) | Yield: 2.96%
- Vanguard Long-Term Bond ETF (BLV) | Yield: 4.42%
10 Best Oil Service Stocks To Invest In Right Now: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
Anti-Viral Programs
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
Influenza Program
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.
Advisors' Opinion:- [By Keith Speights]
The words of the great big-band leader Duke Ellington came to mind after hearing the first quarter results from Sarepta Therapeutics (NASDAQ: SRPT ) : "It don't mean a thing." �Here are the highlights from those results -- and why they're practically meaningless.
No comments:
Post a Comment